Another stock that's trading within range of triggering a major breakout trade is Alexza Pharmaceuticals (ALXA - Get Report), which is focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. This stock has been hit hard by the sellers so are in 2012, with shares down by around 38%.
This is another biotech player with a major catalyst on the horizon. This company has a scheduled PDUFA date of Dec. 21 for its Adasuve product, which is designed for the treatment of agitation associated with schizophrenia or biopolar I disorder in adults.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts